Cargando…
Gene therapy for carcinoma of the breast: Genetic toxins
Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to onco...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521210/ https://www.ncbi.nlm.nih.gov/pubmed/11250689 http://dx.doi.org/10.1186/bcr25 |
_version_ | 1782121834611736576 |
---|---|
author | Vassaux, Georges Lemoine, Nick R |
author_facet | Vassaux, Georges Lemoine, Nick R |
author_sort | Vassaux, Georges |
collection | PubMed |
description | Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to oncology, various gene therapy approaches have been developed. Among them, the use of genetic toxins to kill cancer cells selectively is emerging. Two different types of genetic toxins have been developed so far: the metabolic toxins and the dominant-negative class of toxins. This review describes these two different approaches, and discusses their potential applications in cancer gene therapy. |
format | Text |
id | pubmed-521210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
record_format | MEDLINE/PubMed |
spelling | pubmed-5212102004-10-04 Gene therapy for carcinoma of the breast: Genetic toxins Vassaux, Georges Lemoine, Nick R Breast Cancer Res Review Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to oncology, various gene therapy approaches have been developed. Among them, the use of genetic toxins to kill cancer cells selectively is emerging. Two different types of genetic toxins have been developed so far: the metabolic toxins and the dominant-negative class of toxins. This review describes these two different approaches, and discusses their potential applications in cancer gene therapy. 2000 1999-12-17 /pmc/articles/PMC521210/ /pubmed/11250689 http://dx.doi.org/10.1186/bcr25 Text en Copyright © 1999 Current Science Ltd |
spellingShingle | Review Vassaux, Georges Lemoine, Nick R Gene therapy for carcinoma of the breast: Genetic toxins |
title | Gene therapy for carcinoma of the breast: Genetic toxins |
title_full | Gene therapy for carcinoma of the breast: Genetic toxins |
title_fullStr | Gene therapy for carcinoma of the breast: Genetic toxins |
title_full_unstemmed | Gene therapy for carcinoma of the breast: Genetic toxins |
title_short | Gene therapy for carcinoma of the breast: Genetic toxins |
title_sort | gene therapy for carcinoma of the breast: genetic toxins |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521210/ https://www.ncbi.nlm.nih.gov/pubmed/11250689 http://dx.doi.org/10.1186/bcr25 |
work_keys_str_mv | AT vassauxgeorges genetherapyforcarcinomaofthebreastgenetictoxins AT lemoinenickr genetherapyforcarcinomaofthebreastgenetictoxins |